Supernus Pharmaceuticals
SUPN
#4536
Rank
NZ$4.37 B
Marketcap
NZ$75.07
Share price
3.72%
Change (1 day)
-1.29%
Change (1 year)

Earnings for Supernus Pharmaceuticals (SUPN)

Earnings in 2026 (TTM): -NZ$91.46 Million

According to Supernus Pharmaceuticals 's latest financial reports the company's current earnings are NZ$0.77 Billion. In 2025 the company made an earning of -NZ$85.76 Million a decrease over its 2024 earnings that were of NZ$0.14 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Supernus Pharmaceuticals from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -NZ$91.46 Million6.65%
2025 -NZ$85.76 Million-161.15%
2024 NZ$0.14 B1446.62%
2023 NZ$9.06 M-92.36%
2022 NZ$0.11 B-29.8%
2021 NZ$0.16 B-49.79%
2020 NZ$0.33 B12.99%
2019 NZ$0.29 B7.58%
2018 NZ$0.27 B54.9%
2017 NZ$0.17 B84.25%
2016 NZ$96.99 M202.27%
2015 NZ$32.09 M-462.04%
2014 -NZ$8.87 Million-94%
2013 -NZ$0.15 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
NZ$45.43 B-49,701.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
NZ$14.23 B-15,636.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$54.43 B-59,527.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$16.78 B-18,423.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Zogenix
ZGNX
-NZ$0.38 Billion 304.83%๐Ÿ‡บ๐Ÿ‡ธ USA
United Therapeutics
UTHR
NZ$2.84 B-3,202.82%๐Ÿ‡บ๐Ÿ‡ธ USA